turoctocog alfa
Recombinant proteinexperimental
Turoctocog alfa is a recombinant antihemophilic factor VIII used for the treatment of and prophylaxis of bleeding patients with haemophilia A. It is marketed by Novo Nordisk. It was approved in the United States, the European Union, and Japan in 2013. — Wikipedia
Clinical trial activity
22 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
8
Phase 2
13
Phase 3
12
Phase 4
1
Earliest trial started Mar 1, 2009 (NCT00837356)
Timeline
Indications
Approved for
Studied for
Mechanism of action
- Coagulation factor VIIIEXOGENOUS PROTEIN
Coagulation factor VIII exogenous protein
- Coagulation factor VIIISupplementation
F8 supplementation
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaTuroctocog alfa ↗
- ChEMBLCHEMBL2108286 ↗
Also known as
- n8 recombinant factor viii
- n8 rfviii
- nn7008
- novoeight
- recombinant factor viii n8
- turoctocog alfa
- turoctocog alfa
- turoctocog alfa
- turoctocog alfa
- turoctocog alfa
- turoctocog alfa
- turoctocog alfa
- turoctocog alfa
- turoctocog alfa (genetical recombination)
- turoctocog alfa pegol
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05082116 | Phase 3 | Sep 27, 2021 | Novo Nordisk |
| NCT03588741 | Phase 3 | Jun 12, 2018 | Novo Nordisk |
| NCT03528551 | Phase 3 | Apr 30, 2018 | Novo Nordisk |
| NCT03449342 | Phase 4 | Mar 1, 2018 | Novo Nordisk |
| NCT03196297 | Phase 2 | Aug 15, 2017 | Novo Nordisk |
| NCT02994407 | Phase 1 | Jan 30, 2017 | Novo Nordisk |
| NCT02938585 | Phase 3 | Dec 12, 2016 | Novo Nordisk |
| NCT02941354 | Phase 1 | Oct 9, 2016 | Novo Nordisk |
| NCT02920398 | Phase 1 | Oct 4, 2016 | Novo Nordisk |
| NCT02137850 | Phase 3 | Jun 1, 2014 | Novo Nordisk |
| NCT01731600 | Phase 3 | Feb 20, 2013 | Novo Nordisk |
| NCT01692925 | Phase 1 | Dec 1, 2012 | Novo Nordisk |
| NCT01493778 | Phase 3 | Sep 17, 2012 | Novo Nordisk |
| NCT01489111 | Phase 3 | Aug 1, 2012 | Novo Nordisk |
| NCT01480180 | Phase 3 | Jan 30, 2012 | Novo Nordisk |
| NCT01365520 | Phase 1 | Jun 1, 2011 | Novo Nordisk |
| NCT01238367 | Phase 1 | Nov 1, 2010 | Novo Nordisk |
| NCT01205724 | Phase 1 | Sep 1, 2010 | Novo Nordisk |
| NCT01138501 | Phase 3 | Jun 1, 2010 | Novo Nordisk |
| NCT00984126 | Phase 3 | Oct 26, 2009 | Novo Nordisk |
Showing 20 of 22 trials
Page 1 / 2
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novo Nordisk | For profit | 22 | 22 | 4 | 2009 |
1 organizations
Page 1 / 1